Leonard G. Gomella, MD
Dr. Gomella, a member of the Urology Times Editorial Council, is professor and chairman of urology at Thomas Jefferson University, Philadelphia.
Prostate HIFU lands in the U.S. Now what?
"With all this uncertainty, the good news is that men will no longer need to travel to Canada or elsewhere for prostate HIFU therapy," writes Leonard G. Gomella, MD.
Upfront chemo for PCa? Yes, but…
With conflicting data, should docetaxel be used up front in newly diagnosed metastatic disease?
Localized PCa Tx: An evolving landscape
A recent study confirms that treatment choices for localized prostate cancer are not stagnant but continue to evolve, writes Leonard G. Gomella, MD.
RCC sequencing: One good answer
The take-home message is that for sorafenib and sunitinib, sequencing does not appear to be drug dependent and either can be used as first- or second-line therapy.
Optimum prostate Bx: Have we finally agreed?
Since the days of the digitally directed prostate nodule biopsy using the Vim-Silverman needle, the optimum prostate biopsy strategy has evolved.
High-intensity focused ultrasound for prostate cancer: Is it ready for prime time?
HIFU continues to represent a promising minimally invasive approach for many men with prostate cancer. What its exact role will become remains unclear.
Is there a bias against prostate cancer?
The media seems to be more interested in highlighting the cost of new prostate cancer medications than the important progress made in treating the second leading cause of cancer death in men.
PCa prevention with 5-ARIs: What to tell patients
A major breakthrough in the field of prostate cancer research was announced last summer. For the first time in a randomized clinical trial, a drug was found to reduce the risk of prostate cancer. Widely reported headlines such as "Drug might prevent prostate cancer, researchers say" (USA Today, June 25, 2003, page 1) were tempered by reports of the drug's "disturbing" side effects.